Table 4.
Patient characteristics at time of primary diagnosis.
| Total | n = 79 (%) | |
|---|---|---|
| Age | Median: 61 (27–88) | |
| FIGO stage | I-II | 6 (8%) |
| III | 52 (66%) | |
| IV | 21 (26%) | |
| Nodal status | N0 | 18 (23%) |
| N1 | 33 (42%) | |
| Unknown | 28 (35%) | |
| Metastases formation | M0 | 58 (73%) |
| M1 | 21 (27%) | |
| Tumor grading | I-II | 30 (38%) |
| III | 49 (62%) | |
| CTC posa | Before therapy | 16/78 (21%) |
| After therapy | 10/28 (36%) | |
| DTCs posb | Before therapy | 29/78 (37%) |
| Recurrence | No relapse | 23 (29%) |
| Relapse | 42 (53%) | |
| Unknown | 14 (18%) | |
| Platinum-based chemotherapy | No resistance | 51 (65%) |
| Resistance | 13 (16%) | |
| Unknown | 15 (19%) | |
| Overall Survival | 0 | 40 (51%) |
| 1 | 36 (45%) | |
| Unknown | 3 (4%) |
CTC – circulating tumor cell; DTCs – disseminated tumor cells; FIGO – Federation of Gynecology and Obstetrics; M0 – no metastasis formation; M1 – metastasis formation; pN0 – no nodal infestation; pN1 – nodal infestation; aCTCs before therapy could not be determined for one patients, and CTCs after therapy could not be determined for 51 patients; bDTCs before therapy could not be determined for one patient.